Back to Search
Start Over
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
- Source :
-
British journal of cancer [Br J Cancer] 2017 Jan; Vol. 116 (3), pp. 318-323. Date of Electronic Publication: 2017 Jan 12. - Publication Year :
- 2017
-
Abstract
- Background: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified.<br />Methods: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy. A subgroup analysis according to baseline serum lactate dehydrogenase (LDH) levels was carried out.<br />Results: A significant interaction effect between LDH levels and treatment was found in terms of progression-free survival (PFS; P=0.002). Although patients with low LDH levels achieved significant PFS benefit from the continuation of bevacizumab (HR: 0.39 (95% CI: 0.23-0.65)), patients with high levels did not (HR: 1.10 (95% CI: 0.74-1.64)). Consistent results were reported in overall survival (OS; P=0.075).<br />Conclusions: As preclinical evidence suggests that serum LDH may be a marker of tumour angiogenesis activation, low levels may indicate that bevacizumab is still efficacious in inhibiting angiogenesis. Validation of present results in subgroup analyses of other randomised trials of second-line angiogenesis inhibitors is warranted.<br />Competing Interests: LA reports serving on advisory board or having consultant role for Roche, Amgen, Eli-Lilly, Bayer, Novartis, Ipsen; FL reports serving on advisory board for Amgen and Sanofi-Aventis, receiving lecture fees from Sanofi-Aventis, Bayer, Roche and grant support from Roche and Merck Serono; AF reports serving on advisory board for Amgen, Bayer, Merck Serono, Roche and Sanofi-Aventis, receiving lecture fees from Merck Serono, Roche, Amgen, Bayer, Amgen, Bayer, Merck Serono, Roche and Sanofi-Aventis and grant support from Amgen, Merck Serono and Roche; CC reports serving on advisory board for Roche, Bayer, Amgen and Merck Serono and receiving lecture fees from Sanofi-Aventis and Bayer. All remaining authors declared no conflicts of interest.
- Subjects :
- Adenocarcinoma pathology
Adult
Aged
Biomarkers, Tumor blood
Chemotherapy, Adjuvant
Colorectal Neoplasms pathology
Disease Progression
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Prognosis
Treatment Outcome
Adenocarcinoma drug therapy
Angiogenesis Inhibitors therapeutic use
Bevacizumab therapeutic use
Colorectal Neoplasms drug therapy
L-Lactate Dehydrogenase blood
Subjects
Details
- Language :
- English
- ISSN :
- 1532-1827
- Volume :
- 116
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- British journal of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 28081548
- Full Text :
- https://doi.org/10.1038/bjc.2016.413